Sangamo enters into asset sale agreements with Lilly and Astellas

Additional information about the Chapter 11 reorganization and asset sales is available through Sangamo's noticing agent at https://www.veritaglobal.net/SangamoTherapeutics.

Presentation

Poster: Anti-AAV6 antibody assay for patient enrollment supporting ST-920 phase 1/2 study for Fabry disease

Liching Cao, Sangamo Therapeutics

  • Poster Session: Thursday, February 8, 2024 – 3-5pm PT (Poster: 048)

Download PDF